Arthneeti
All Q2 FY26 results →
AM

Aakaar Medical Technologies Ltd

Q2 FY26Personal Products

Aakaar Medical Technologies Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹61
Market cap₹95 Cr
P/E14.3
Updated23 Aug 2026
Read4 min read

The short version

Targeting 25%-30% CAGR growth over the next 3 years, aiming to maintain growth momentum. Targeting 25%-30% growth momentum in FY26, aiming to retain a strong CAGR over the next 3 years.

From Aakaar Medical Technologies Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Targeting 25%-30% CAGR growth over the next 3 years, aiming to maintain growth momentum.
  • Confident in ending FY26 on a positive note with better revenue than FY25, despite current stringent credit controls affecting short-term sales.
  • Added around 900 new customers in H1 FY26 and 2,600+ customers in the prior year, indicating strong customer base expansion.
  • Investing in new product launches, including FDA-approved dermal fillers and botulinum toxins, expected to boost market share and revenue.
  • Expanding home care and consumable product categories to increase per customer usage and overall sales.
  • Focused on improving cash flow and reducing receivable days to below 100 to promote sustainable growth.

2 more points from Aakaar Medical Technologies Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Aakaar Medical Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Aakaar Medical Technologies has invested in infrastructure including its own logistics supply chain, software for billing, reporting, and MIS.
  • Post-funding, the company has relaxed in terms of working capital and plans to invest significantly in marketing, especially Direct-to-Consumer (D2C) marketing to create the market.
  • They are focusing on building doctor-driven credibility rather than immediate e-commerce presence, aiming for organic growth without burning money on online marketing initially.
  • The company is investing in backend operations and technology to support collaboration with multinational companies to launch their brands in India.
  • They have launched new devices such as triposcopic and dermatoscopic devices with subscription models, pending full-scale launch.

2 more points from Aakaar Medical Technologies Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Personal Products

Ranked on what management guided this quarter

Guidance-ranked
1Anondita Medi.
Rev 1Mar 1
2Honasa Consumer Ltd
Rev 2Mar 2
3
Rev 3Mar 3
4
Rev 3Mar 3
5
Rev 3Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aakaar Medical Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers. However, relevant points indicating demand and order trends include: - Demand starts increasing post-Diwali due to seasonal factors, typically in H2. - Sales team converts demand daily; no corporate-level bulk ordering mentioned. - Inventory in the market is reducing due to stringent control on receivables. - There is an anticipated upside in demand and revenue in the second half of the fiscal year. - Company aims to maintain a 25%-30% CAGR growth over the next 3 years. - Added around 900 new customers in the first half of the year; over 2,600 last year.

2 more points from Aakaar Medical Technologies Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Continue your research

What Aakaar Medical's management said in earlier quarters

Others in Personal Products this season

  • Honasa Consumer Ltd (Q2 FY26)

    Quick commerce channel is rapidly growing, currently about 10% of revenues, with healthy economics and fastest-growing channel. Key concall takeaways from…

  • Godrej Consumer Products Ltd (Q2 FY26)

    Volume growth trajectory around 7-8% for the next four quarters after adjusting for GST-related noise. Key concall takeaways from Godrej Consumer's Q2 FY26…

  • Dabur India Ltd (Q2 FY26)

    Rural growth is robust at around 7%, driven by initiatives like LUP bundles and expansion in rural distribution. Key concall takeaways from Dabur India Ltd's…

  • Emami Ltd (Q2 FY26)

    GST-driven price cuts (~INR 250-260 crores impact on MRP) intended to boost demand and consumer affordability. Key concall takeaways from Emami's Q2 FY26…

Compare:vs Godrej Consumer Products Ltdvs Dabur India Ltdvs Colgate-Palmolive (India) Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aakaar Medical Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aakaar Medical Technologies Ltd Q2 FY26 results?

Targeting 25%-30% CAGR growth over the next 3 years, aiming to maintain growth momentum. Targeting 25%-30% growth momentum in FY26, aiming to retain a strong CAGR over the next 3 years.

What is Aakaar Medical Technologies Ltd share price analysis?

Aakaar Medical Technologies Ltd currently shows a neutral. The stock trades at a P/E of 14.3 with a market cap of ₹95 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aakaar Medical Technologies Ltd planning capital expenditure?

Aakaar Medical Technologies has invested in infrastructure including its own logistics supply chain, software for billing, reporting, and MIS.

Keep Aakaar Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.